Suppr超能文献

EphA3 靶向减少多发性骨髓瘤细胞的体外黏附和侵袭以及体内生长和血管生成。

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

机构信息

Laboratory of Pre-clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata (CROB), via Padre Pio, 1, 85028, Rionero in Vulture, Italy.

Laboratorio di Oncologia, IRCCS - G. Gaslini Institute, Genoa, Italy.

出版信息

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

Abstract

PURPOSE

Multiple myeloma (MM) is a hematologic malignancy characterized by a clonal expansion of plasma cells (PCs) in the bone marrow (BM). Since MM has so far remained incurable, further insights into its pathogenesis and the concomitant identification of new therapeutic targets are urgently needed. The tyrosine kinase receptor EphA3 is known to be involved in various cellular processes including cell viability, cell movement and cell-cell interactions. Recently, EphA3 has emerged as a potential therapeutic target in several hematologic and solid tumors. Here, we aimed to uncover the role of EphA3 in MM.

METHODS

EphA3 mRNA and protein expression in primary MM bone marrow plasma cells (BMPCs), in MM-derived cell lines and in healthy controls (HCs) was assessed using qRT-PCR, Western blotting and flow cytometry. The effects of siRNA-mediated EphA3 silencing and anti EphA3 antibody (EphA3mAb) treatment on MM PC trafficking and viability were evaluated using in vitro assays. The effects of EphA3mAb treatment were also assessed in two MM-derived mouse xenograft models.

RESULTS

We found that EphA3 was overexpressed in primary MM BMPCs and MM-derived cell lines compared to HCs. We also found that siRNA-mediated EphA3 silencing and EphA3mAb treatment significantly inhibited the ability of MM PCs to adhere to fibronectin and stromal cells and to invade in vitro, without affecting cell proliferation and viability. Gene expression profiling showed that EphA3 silencing resulted in expression modulation of several molecules that regulate adhesion, migration and invasion processes. Importantly, we found that EphA3mAb treatment significantly inhibited in vivo tumor growth and angiogenesis in two MM-derived mouse xenograft models.

CONCLUSIONS

Our findings suggest that EphA3 plays an important role in the pathogenesis of MM and provide support for the notion that its targeting may represent a novel therapeutic opportunity for MM.

摘要

目的

多发性骨髓瘤(MM)是一种血液恶性肿瘤,其特征是骨髓(BM)中浆细胞(PC)的克隆性扩张。由于迄今为止 MM 仍然无法治愈,因此迫切需要进一步了解其发病机制并同时确定新的治疗靶点。酪氨酸激酶受体 EphA3 已知参与多种细胞过程,包括细胞活力、细胞运动和细胞-细胞相互作用。最近,EphA3 已成为几种血液学和实体瘤的潜在治疗靶点。在这里,我们旨在揭示 EphA3 在 MM 中的作用。

方法

使用 qRT-PCR、Western blot 和流式细胞术评估 EphA3 mRNA 和蛋白在原发性 MM 骨髓浆细胞(BMPC)、MM 衍生细胞系和健康对照(HC)中的表达。使用体外测定法评估 siRNA 介导的 EphA3 沉默和抗 EphA3 抗体(EphA3mAb)治疗对 MM PC 迁移和活力的影响。还在两种 MM 衍生的小鼠异种移植模型中评估了 EphA3mAb 治疗的效果。

结果

我们发现 EphA3 在原发性 MM BMPC 和 MM 衍生细胞系中表达高于 HC。我们还发现,siRNA 介导的 EphA3 沉默和 EphA3mAb 治疗显著抑制了 MM PC 黏附纤维连接蛋白和基质细胞以及体外侵袭的能力,而不影响细胞增殖和活力。基因表达谱分析显示,EphA3 沉默导致调节黏附、迁移和侵袭过程的几个分子的表达调节。重要的是,我们发现 EphA3mAb 治疗在两种 MM 衍生的小鼠异种移植模型中显著抑制了体内肿瘤生长和血管生成。

结论

我们的研究结果表明,EphA3 在 MM 的发病机制中起重要作用,并支持其靶向治疗可能代表 MM 的一种新的治疗机会的观点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验